CD73 in hepatobiliopancreatic system: a potential target for immunotherapy and additional tool for the pathological diagnosis

Sciarra, A.; Monteiro, I.; Ménétrier‐Caux, Christine; Rosa, Stefano La; Romero, Pedro; Sempoux, C.; Leval, Laurence de

doi:10.26226/morressier.5b4709886f4cb300109517d6

Cited by 1 publication

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…1): S124, 2018. [1] ABSTRACT Background: the tumor-expressed CD73 ectonucleotidase generates immune tolerance and promotes invasiveness via adenosine production from degradation of AMP. While anti-CD73 blockade treatment is a promising tool in cancer immunotherapy, a characterization of CD73 expression in human hepatobiliopancreatic system is lacking.…”

Section: Note On Previous Publicationmentioning

confidence: 99%

See 1 more Smart Citation

CD73 expression in normal and pathological human hepatobiliopancreatic tissues

Sciarra

Monteiro

Ménétrier‐Caux

et al. 2019

Cancer Immunol Immunother

Self Cite

View full text Add to dashboard Cite

Background: the tumor-expressed CD73 ectonucleotidase generates immune tolerance and promotes invasiveness via adenosine production from degradation of AMP. While anti-CD73 blockade treatment is a promising tool in cancer immunotherapy, a characterization of CD73 expression in human hepatobiliopancreatic system is lacking. Patients and methods: CD73 expression was investigated by immunohistochemistry in a variety of non-neoplastic and neoplastic conditions of the liver, pancreas and biliary tract. Results: CD73 was expressed in normal hepatobiliopancreatic tissues with subcellularspecific patterns of staining: canalicular in hepatocytes, and apical in cholangiocytes and pancreatic ducts. CD73 was present in all hepatocellular carcinoma (HCC), in all pancreatic ductal adenocarcinoma (PDAC), and in the majority of intra and extrahepatic cholangiocellular carcinomas, whereas it was detected only in a subset of pancreatic neuroendocrine neoplasms and almost absent in acinar cell carcinoma. In addition to the canonical pattern of staining, an aberrant membranous and/or cytoplasmic expression was observed in invasive lesions, especially in HCC and PDAC. These two entities were also characterized by a higher extent and intensity of staining as compared to other hepatobiliopancreatic neoplasms. In PDAC, aberrant CD73 expression was inversely correlated with differentiation (p<0.01) and was helpful to identify isolated discohesive tumor cells. Additionally, increased CD73 expression was associated with reduced overall survival (HR 1.013) and loss of E-Cadherin. Conclusions: consistent CD73 expression supports the rationale for testing anti-CD73 therapies in patients with hepatobiliopancreatic malignancies. Specific patterns of expression could also be of help in the routine diagnostic workup.

show abstract

Section: Note On Previous Publicationmentioning

confidence: 99%

“…4A)(Table 2). No variation in CD73 staining was noted according to the degree of dysplasia.By contrast, CD73 was expressed in all cases of invasive PDAC, with a median value of 80% of positive TC (5-95%) and a median intensity of 2(1)(2)(3). TC with intensity=3 were noted in most of cases (26/42, 62%) (Table 1).…”

mentioning

confidence: 97%